3279 documents avec fichiers associés – 5422 références bibliographiques  [english version]
HAL : hal-00282619, version 1

Fiche détaillée  Récupérer au format
Journal of Virology 78, 11 (2004) 5728-36
Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents.
Sabine Bonnenfant 1, Claire Marie Thomas 1, Claudio Vita 2, Frédéric Subra 3, Eric Deprez 3, Fatima Zouhiri 4, Didier Desmaële 5, Jean D'Angelo 5, Jean-François Mouscadet 3, 6, Hervé Leh ( ) 3, 4
(06/2004)

We have previously shown that styrylquinolines (SQLs) are integrase inhibitors in vitro. They compete with the long terminal repeat substrate for integrase. Here, we describe the cellular mode of action of these molecules. We show that SQLs do not interfere with virus entry. In fact, concentrations of up to 20 times the 50% inhibitory concentration did not inhibit cell-to-cell fusion or affect the interaction between GP120 and CD4 in vitro. Moreover, the pseudotype of the retrovirus envelope did not affect drug activity. Quantitative reverse transcription PCR experiments showed that SQLs do not inhibit the entry of the genomic RNA. In contrast, the treatment of human immunodeficiency virus type 1-infected cells with SQLs reduced the amount of the late cDNA, suggesting for the first time that integrase targeting molecules may affect the accumulation of DNA during reverse transcription. The cellular target of SQLs was confirmed by the appearance of mutations in the integrase gene when viruses were grown in the presence of increasing concentrations of SQLs. Finally, these mutations led to SQL-resistant viruses when introduced into the wild-type sequence. In contrast, SQLs were fully active against reverse transcriptase inhibitor- and diketo acid-resistant viruses, positioning SQLs as a second group of anti-integrase compounds.
1 :  Bioalliance Pharma SA
Bioalliance Pharma
2 :  Département d'Ingénierie et d'Etudes des Protéines
CEA : SACLAY
3 :  Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée (LBPA)
CNRS : UMR8113 – École normale supérieure de Cachan - ENS Cachan
4 :  Bioalliancepharma
Bioalliancepharma
5 :  Molécules bioactives, conception, isolement et synthèse (MBCIS)
CNRS : UMR8076 – Université Paris XI - Paris Sud
6 :  Laboratoire de Biotechnologie et Pharmacogénétique Appliquée (LBPA)
Ecole normale supérieure de Paris - ENS Paris – CNRS : UMR8532
Sciences du Vivant/Biochimie, Biologie Moléculaire/Biologie moléculaire